← ANALYST RATINGS · TIPRANKS
Artiva Biotherapeutics, Inc. (ARTV): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $41.00, the highest $41.00, the lowest $41.00. The average is +600.9% from the last price of $5.85.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.00 → $5.50−8.3% | Hold | −6.0% | Reiterated | 17.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.00 → $5.50−8.3% | Hold | −6.0% | Reiterated | 17.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.00 → $5.50−8.3% | Hold | −6.0% | Reiterated | 17.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.00 → $5.50−8.3% | Sell | −6.0% | Downgrade | 15.10.26on TipRanks 08:07 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.00 → $5.50−8.3% | Sell | −6.0% | Downgrade | 15.10.26on TipRanks 08:07 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.00 → $6.00−14.3% | Hold | +2.6% | Reiterated | 14.10.26on TipRanks 01:05 | — | |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $41.00 | Buy | +600.9% | Reiterated | 01.10.26on TipRanks 12:11 | −4.8%next day −0.2% · 5 days −1.2% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $35.00 | Buy | +498.3% | Reiterated | 01.10.26on TipRanks 10:55 | −4.8%next day −0.2% · 5 days −1.2% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 07.08.26on TipRanks 08:25 | −3.3%next day −0.4% · 5 days +1.2% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $40.00 | Buy | +583.8% | Reiterated | 25.05.26on TipRanks May 26 08:35 | −3.2%next day −0.5% · 5 days −11.6% | ↗ |
| Unknown Analyst | Jefferies | $19.00 → $23.00+21.1% | Buy | +293.2% | Reiterated | 21.05.26on TipRanks May 26 08:35 | +1.7%next day −1.9% · 5 days −2.6% | ↗ |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $40.00 | Buy | +583.8% | Reiterated | 21.05.26on TipRanks 09:35 | +1.7%next day −1.9% · 5 days −2.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Artiva Biotherapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $38.00 at a price of $7.12 (+433.7%); now: $38.00 at $5.85 (+549.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 7 | 7 | 2 | 1 | 2 |
| Buy | 3 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.55 (from $-0.56 to $-0.53). Last quarter: $-0.63.
Best top-analyst consensus in the sector · Healthcare
About Artiva Biotherapeutics, Inc.
- CEO: Fred Aslan
- Employees: 115
- 5505 Morehouse Drive, San Diego, CA, 92121, US
- www.artivabio.com
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Data from the stock’s TipRanks forecast page, read 162 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗